Search

Your search keyword '"Fresta, Massimo"' showing total 622 results
Start Over Author "Fresta, Massimo"
622 results on '"Fresta, Massimo"'

6. Hierarchical microplates as drug depots with controlled geometry, rigidity and therapeutic efficacy

Author

Di Francesco, Martina, Primavera, Rosita, Romanelli, Davide, Palomba, Roberto, Catelani, Tiziano, Celia, Christian, Di Marzio, Luisa, Fresta, Massimo, Di Mascolo, Daniele, and Decuzzi, Paolo

Subjects
Quantitative Biology - Quantitative Methods
Abstract

A variety of microparticles have been proposed for the sustained and localized delivery of drugs whit the objective of increasing therapeutic indexes by circumventing filtering organs and biological barriers. Yet, the geometrical, mechanical and therapeutic properties of such microparticles cannot be simultaneously and independently tailored during the fabrication process in order to optimize their performance. In this work, a top-down approach is employed to realize micron-sized polymeric particles, called microPlates (uPLs), for the sustained release of therapeutic agents. uPLs are square hydrogel particles, with an edge length of 20 um and a height of 5 um, made out of poly (lactic co glycolic acid) (PLGA). During the synthesis process, the uPL Young's modulus can be varied from 0.6 to 5 MPa by changing PLGA amounts from 1 to 7.5 mg, without affecting the uPL geometry. Within the porous uPL matrix, different classes of therapeutic payloads can be incorporated including molecular agents, such as the anti-inflammatory dexamethasone (DEX), and nanoparticles, containing themselves imaging and therapeutic molecules. As a proof of principle, uPLs are loaded with free DEX and 200 nm spherical polymeric nanoparticles, carrying DEX molecules (DEX-SPNs). Electron and fluorescent confocal microscopy analyses document the uniform distribution and stability of molecular and nano agents within the uPL matrix. This multiscale, hierarchical microparticle releases DEX for at least 10 days. The inclusion of DEX-SPNs serves to minimize the initial burst release and modulate the diffusion of DEX molecules out of the uPL matrix. The pharmacological and therapeutic properties together with the fine tuning of geometry and mechanical stiffness make uPLs a unique polymeric depot for the potential treatment of cancer, cardiovascular and chronic, inflammatory diseases.

Published
2019

12. Conventional Nanosized Drug Delivery Systems for Cancer Applications

Author

Vergallo, Cristian, Hafeez, Muhammad Nadeem, Iannotta, Dalila, Santos, Hélder A., D’Avanzo, Nicola, Dini, Luciana, Cilurzo, Felisa, Fresta, Massimo, Di Marzio, Luisa, Christian, Celia, Crusio, Wim E., Series Editor, Dong, Haidong, Series Editor, Radeke, Heinfried H., Series Editor, Rezaei, Nima, Series Editor, Fontana, Flavia, editor, and Santos, Hélder A., editor

Published
2021
Full Text
View/download PDF

19. OX26-cojugated gangliosilated liposomes to improve the post-ischemic therapeutic effect of CDP-choline.

Author

d'Avanzo, Nicola, Paolino, Donatella, Barone, Antonella, Ciriolo, Luigi, Mancuso, Antonia, Christiano, Maria Chiara, Tolomeo, Anna Maria, Celia, Christian, Deng, Xiaoyong, and Fresta, Massimo

Abstract

Cerebrovascular impairment represents one of the main causes of death worldwide with a mortality rate of 5.5 million per year. The disability of 50% of surviving patients has high social impacts and costs in long period treatment for national healthcare systems. For these reasons, the efficacious clinical treatment of patients, with brain ischemic stroke, remains a medical need. To this aim, a liposome nanomedicine, with monosialic ganglioside type 1 (GM1), OX26 (an anti-transferrin receptor antibody), and CDP-choline (a neurotrophic drug) (CDP-choline/OX26Lip) was prepared. CDP-choline/OX26Lip were prepared by a freeze and thaw method and then extruded through polycarbonate filters, to have narrow size distributed liposomes of ~80 nm. CDP-choline/OX26Lip were stable in human serum, they had suitable pharmacokinetic properties, and 30.0 ± 4.2% of the injected drug was still present in the blood stream 12 h after its systemic injection. The post-ischemic therapeutic effect of CDP-choline/OX26Lip is higher than CDP-choline/Lip, thus showing a significantly high survival rate of the re-perfused post-ischemic rats, i.e. 96% and 78% after 8 days. The treatment with CDP-choline/OX26Lip significantly decreased the peroxidation rate of ~5-times compared to CDP-choline/Lip; and the resulting conjugated dienes, that was 13.9 ± 1.1 mmol/mg proteins for CDP-choline/Lip and 3.1 ± 0.8 for CDP-choline/OX26Lip. OX26 increased the accumulation of GM1-liposomes in the brain tissues and thus the efficacious of CDP-choline. Therefore, this nanomedicine may represent a strategy for the reassessment of CDP-choline to treat post-ischemic events caused by brain stroke, and respond to a significant clinical need. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

47. Ammonium Glycyrrhizinate-Loaded Niosomes as a Potential Nanotherapeutic System for Anti-Inflammatory Activity in Murine Models [Retraction]

Author

Marianecci, Carlotta, primary, Rinaldi, Federica, additional, Di Marzio, Luisa, additional, Mastriota, Marica, additional, Pieretti, Stefano, additional, Celia, Christian, additional, Paolino, Donatella, additional, Iannone, Michelangelo, additional, Fresta, Massimo, additional, and Carafa, Maria, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results